Market Chatter: France-US-Based Immunotherapy Firm TheraVectys Mulls Hong Kong IPO
MT Newswires Live01-07 09:59
TheraVectys SA is considering an initial public offering in Hong Kong, Bloomberg News reported Tuesday, citing people familiar with the matter.
The France- and US-based immunotherapy company is working with advisers on a potential share sale that could raise a few hundred million dollars and may take place as soon as this year, the report said.
Deliberations are ongoing, and no final decision has been made, it added.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
